| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| J0178 |
Injection, aflibercept, 1 mg |
36,113 |
20,428 |
$18.22M |
| J2777 |
Injection, faricimab-svoa, 0.1 mg |
4,442 |
2,093 |
$2.08M |
| 67028 |
Intravitreal injection of a pharmacologic agent |
48,227 |
28,891 |
$1.55M |
| J2778 |
Injection, ranibizumab, 0.1 mg |
2,750 |
2,183 |
$1.33M |
| 92250 |
|
19,570 |
15,844 |
$543K |
| 92012 |
Ophthalmological services: medical examination and evaluation, intermediate, established patient |
31,744 |
23,638 |
$415K |
| 92014 |
Ophthalmological services: medical examination and evaluation, comprehensive, established patient |
20,379 |
16,180 |
$402K |
| 92134 |
|
49,132 |
34,947 |
$349K |
| 67228 |
|
1,309 |
873 |
$157K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
3,034 |
2,524 |
$154K |
| J3590 |
Unclassified biologics |
311 |
144 |
$116K |
| 92235 |
|
2,922 |
2,444 |
$101K |
| 92226 |
|
9,427 |
7,342 |
$88K |
| J0177 |
Injection, aflibercept hd, 1 mg |
153 |
68 |
$73K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
1,368 |
1,076 |
$42K |
| J9035 |
Injection, bevacizumab, 10 mg |
914 |
661 |
$28K |
| J2781 |
Injection, pegcetacoplan, intravitreal, 1 mg |
117 |
45 |
$26K |
| 92202 |
|
10,186 |
7,937 |
$25K |
| 67210 |
|
128 |
102 |
$24K |
| J0179 |
Injection, brolucizumab-dbll, 1 mg |
39 |
32 |
$13K |
| 99215 |
Prolong outpt/office vis |
254 |
206 |
$11K |
| 76512 |
|
136 |
121 |
$6K |
| 92225 |
|
423 |
352 |
$6K |
| 92020 |
|
388 |
309 |
$3K |
| 99205 |
Prolong outpt/office vis |
52 |
47 |
$3K |
| 92201 |
|
517 |
401 |
$1K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
104 |
67 |
$815.67 |
| 76510 |
|
33 |
13 |
$667.36 |
| 99072 |
|
13 |
13 |
$0.00 |